Ascentage Pharma Group

Ascentage Pharma is a biopharmaceutical company focused on discovering, developing and commercializing therapies for hematological malignancies, with lead assets olverembatinib and lisaftoclax. Its first lead asset, olverembatinib, is the first and only third-generation BCR-ABL1 TKI approved in China for CML patients. Its second lead asset, lisaftoclax (APG-2575), is a novel Bcl-2 inhibitor approved by China's NMPA for adult CLL/SLL patients after at least one systemic therapy that included BTK inhibitors.

Its lead assets, olverembatinib and lisaftoclax, target major hematological malignancies including CML, AML, CLL, ALL, MDS and multiple myeloma.